Iovance Biotherapeutics, Inc. (LON:0JDK)

Market Cap	1.39B
Revenue (ttm)	67.79M
Net Income (ttm)	-305.90M
Shares Out	n/a
EPS (ttm)	-1.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,467
Average Volume	29,691
Open	5.67
Previous Close	5.58
Day's Range	5.67 - 6.09
52-Week Range	3.22 - 18.31
Beta	0.53
RSI	44.94
Earnings Date	Feb 24, 2025

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combinat...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2007
• Employees: 557
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0JDK

Financial Performance

Financial numbers in USD